Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06663332

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants (TRILOGY)

A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

Sponsor: Janssen Research & Development, LLC

Conditions Arthritis, Juvenile Arthritis, Psoriatic Colitis, Ulcerative Crohns Disease

Interventions Guselkumab

Updated 16 times since 2024 Last updated: Mar 12, 2026 Started: Oct 29, 2024 Primary completion: Dec 12, 2031 Completion: Dec 12, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06663332, this PHASE3 trial focuses on Arthritis, Juvenile and Arthritis, Psoriatic and remains actively recruiting participants. Sponsored by Janssen Research & Development, LLC, it has been updated 16 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

16 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3

▶ Show 11 earlier versions

Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Jan 2025 [monthly]

Recruiting PHASE3

First recorded

Oct 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Atlanta, United States , Beijing, China , Bergamo, Italy , Bologna, Italy , Braga, Portugal , Changzhou, China , Cincinnati, United States , Hamburg, Germany , Hangzhou, China and 17 more locations